• Mashup Score: 0
    AMBASSADOR: Pembrolizumab Meets DFS Threshold in Patients With MIBC After Surgery - 6 month(s) ago

    Merck has announced that the phase 3 AMBASSADOR trial (KEYNOTE-123) evaluating KEYTRUDA (pembrolizumab) has met one of its dual primary endpoints of disease-free survival (DFS) for the adjuvant treatment of patients with localized muscle-invasive bladder cancer (MIBC) and locally advanced urothelial carcinoma. “Up to half of patients with bladder cancer who undergo surgery will experience recurrence within a year, underscoring the need for new treatment options in the adjuvant setting,” said Marjorie

    Source: guoncologynow.com
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of GUOncologyNow
      GUOncologyNow

      In a recent press release, @Merck has announced that the phase 3 AMBASSADOR trial evaluating #pembrolizumab for the adjuvant treatment of #MIBC has met one of its dual primary endpoints of DFS. Read more: https://t.co/jR7AOUU9u2 https://t.co/ex557m7dTO

  • Mashup Score: 0
    FDA Approves Pembrolizumab for Neoadjuvant, Adjuvant Treatment of Resectable NSCLC - 6 month(s) ago

    The US Food and Drug Administration (FDA) has approved pembrolizumab with platin um-containing chemotherapy as neoadjuvant treatment and the continuation of single-agent pembrolizumab as postsurgical adjuvant therapy for resectable non-small cell lung cancer (NSCLC). Treatment efficacy was assessed in KEYNOTE-671, a multicenter, randomized, double-blind, placebo-controlled trial consisting of 797 patients with previously untreated and resectable stage II, IIIA, or IIIB NSCLC. The study population was

    Source: docwirenews.com
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of mydocwire
      mydocwire

      The #FDA has approved #pembrolizumab with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as post-surgical adjuvant therapy for resectable #NSCLC. https://t.co/J3Kr1hr908 https://t.co/3clXdKVAzU

  • Mashup Score: 51
    Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC) - Merck.com - 6 month(s) ago

    KEYTRUDA® (pembrolizumab) is the first anti-PD-1 therapy to demonstrate statistically significant improvement in OS as a neoadjuvant and adjuvant treatment versus pre-operative chemotherapy for NSCLC Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Phase 3 KEYNOTE-671 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB (T3-4N2) non-small cell lung cancer (NSCLC) met its dual primary endpoint of overall survival (OS). At a pre-specified interim analysis, KEYTRUDA plus chemotherapy before surgery (neoadjuvant), followed by resection and KEYTRUDA as a single agent after surgery (adjuvant), demonstrated a statistically significant and clinically meaningful improvement in OS compared to neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in these patients. The safety profile of KEYTRUDA was consistent with that observed in previously

    Source: www.merck.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DrChoueiri
      DrChoueiri

      JUST IN: KEYNOTE-671 OS + for EFS AND OS!!!! -NSCLC Stage II, IIIA or IIIB (T3-4N2) -Pembrolizumab is the first PD1 drug with OS in a perioperative setting! -Initially presented at #ASCO23 -Update at #ESMO23 https://t.co/rvGAQCu1yI @OncoAlert @myESMO @OncBrothers https://t.co/unbjYU8Atv https://t.co/vGyoOx3Oh4

    • Profile photo of RManochakian
      RManochakian

      🔥@OncoAlert Hot off the press Merck announces #KEYNOTE671 trial, #Neoadjuvant #Pembrolizumab (vs placebo) + chemo followed by #Adjuvant pembro (vs placebo) in pts with resectable stage II,IIIA or IIIB #NSCLC meets primary endpoint of #OverallSurvival. 👇🏼 https://t.co/gJtIzuB4xV https://t.co/CPDSHjQwOg

  • Mashup Score: 0
    EV-302: EV Plus Pembrolizumab Improves OS, PFS in Untreated, Advanced Urothelial Carcinoma - 7 month(s) ago

    The phase 3 KEYNOTE-A39/EV-302 study has met its dual primary end points of overall survival (OS) and progression-free survival (PFS) in previously untreated, locally advanced or metastatic urothelial carcinoma (la/mUC), according to the latest topline results. The trial assessed the combination of enfortumab vedotin-ejfv (EV) plus pembrolizumab versus chemotherapy (gemcitabine plus cisplatin or carboplatin). Investigators enrolled patients who may or may not be eligible for treatment with cisplatin-based

    Source: guoncologynow.com
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of GUOncologyNow
      GUOncologyNow

      The phase 3 EV-302 study met its primary end points of OS and PFS in patients with previously untreated, locally advanced or metastatic #urothelialcarcinoma, demonstrating the continued efficacy of enfortumab vedotin-ejfv plus #pembrolizumab. Learn more: https://t.co/sLyvRu9Ook https://t.co/1bkBn68TDQ

Load More